Crossmark

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

Crossref DOI link: https://doi.org/10.1186/s13045-019-0732-7

Published Online: 2019-05-16

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Yingxi

Liu, Qian

Zhong, Mengjun

Wang, Zhenzhen

Chen, Zhaoqi

Zhang, Yu

Xing, Haiyan

Tian, Zheng

Tang, Kejing

Liao, Xiaolong

Rao, Qing

Wang, Min

Wang, Jianxiang https://orcid.org/0000-0001-9437-9151
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81700163, 81830005, 81770181)

National Key Research and Development Program for Precision Medicine (2017YFC0909800)

Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81421002)

CAMS Initiative Fund for Medical Sciences (2016-I2M-1-007, 2017-I2M-1-015)

PUMC Youth Fund and the Fundamental Research Funds for the Central Universities (2017310024)
License Information

Text and Data Mining valid from 2019-05-16

Version of Record valid from 2019-05-16
More Information

Article History

Received: 22 February 2019

Accepted: 10 April 2019

First Online: 16 May 2019

Ethics approval and consent to participate

: Peripheral blood of healthy donors was obtained from the Tianjin Blood Center under the approval by the ethical advisory board of the Institute of Hematology and Blood Diseases Hospital. All animal experiments were approved by the ethical advisory board of the Institutional Animal Care and Use Committee of Peking Union Medical College.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below